Resolution Therapeutics Secures £63.5 Million Funding Round
Resolution Therapeutics, a forward-thinking and innovative biopharmaceutical company based in the vibrant cities of Edinburgh, Scotland, and London, UK, has successfully secured £63.5 million in a Series B funding round. This significant financing effort was spearheaded by Syncona Ltd, a prominent investor in the life sciences sector. In conjunction with this substantial financial boost, the company announced a key leadership change, bringing on board Paul Sekhri, a highly regarded executive with extensive experience in drug development and business strategy, to serve as the Chair of the Board of Directors. This strategic appointment is expected to enhance the company's governance and drive its ambitious growth plans.
The primary objective of Resolution Therapeutics following this funding injection is to propel forward its lead candidate, RTX001.
This innovative therapy is an autologous, engineered, pro-regenerative macrophage cell treatment specifically tailored to deliver groundbreaking outcomes for patients grappling with end-stage liver disease. Under the dynamic leadership of CEO Amir Hefni, the company is committed to harnessing advanced macrophage therapy techniques to improve the regenerative capabilities of these immune cells, targeting the treatment of both inflammatory and fibrotic diseases. By leveraging an advanced proprietary platform for cell characterization and engineering, Resolution Therapeutics is positioned to create autologous macrophages with unique pro-regenerative characteristics, ultimately enhancing patient outcomes.
In addition to its focus on RTX001, Resolution Therapeutics is diligently exploring opportunities to extend the capabilities of its innovative platform into new therapeutic areas beyond liver disease. The potential for engineered macrophages to address various pathological conditions presents a transformative opportunity in the field of regenerative medicine. The preclinical data supporting RTX001’s first-in-class potential, showcasing both anti-fibrotic and anti-inflammatory properties compared to non-engineered macrophages, underscores the company’s commitment to addressing significant unmet medical needs. As Resolution Therapeutics continues to advance its research and development efforts, it remains poised to make a lasting impact on the treatment landscape for patients suffering from challenging inflammatory and fibrotic diseases.
They've invested in Resolution Therapeutics
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK